BC Week In Review | Jun 29, 2015
Company News

GlaxoSmithKline, Pfizer deal

GlaxoSmithKline will sell quadrivalent meningitis vaccines Nimenrix and Mencevax to Pfizer for EUR115 million ($130.2 million) to address competition concerns raised by the European Commission. Earlier this year, GSK acquired meningitis vaccines Menveo and Bexsero...
BC Extra | Jun 23, 2015
Company News

Pfizer acquires two meningitis vaccines from GSK

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) will sell quadrivalent meningitis vaccines Nimenrix and Mencevax to Pfizer Inc. (NYSE:PFE) for EUR 115 million ($130.2 million) to address competition concerns raised by the European Commission. Earlier this year, GSK...
BC Week In Review | Aug 12, 2013
Clinical News

Menveo regulatory update

FDA approved an sBLA from Novartis to expand the label of Menveo vaccine for prevention of meningococcal disease caused by Neisseria meningitides groups A, C, W-135 and Y to include children >=2 months. The vaccine...
BC Week In Review | May 13, 2013
Clinical News

Menveo regulatory update

EMA's CHMP issued a negative opinion recommending against expanding the label for Novartis' Menveo vaccine against invasive disease caused by Neisseria meningitides groups A, C, W135 and Y to include children ages 2-23 months. CHMP...
BioCentury | Oct 1, 2012
Finance

3Q Stock Wrap-Up: Back in black

Large cap biotechs stormed back after a weak 2Q12 to post a 7% gain for a third quarter in which every market cap segment finished in the black, albeit just barely for the micro-caps. For...
BC Week In Review | Mar 19, 2012
Clinical News

Menveo regulatory update

EMA's CHMP issued a positive opinion recommending approval of a label expansion for Menveo meningitis vaccine to include children ages 2-11 years of age. The vaccine is already approved to prevent invasive disease in people...
BC Extra | Mar 16, 2012
Company News

CHMP recommends label expansion for Menveo

EMA's CHMP issued a positive opinion on a proposed label expansion for Menveo meningitis vaccine from Novartis AG (NYSE:NVS; SIX:NOVN) to include children ages 2-11 years of age. The vaccine is already approved to prevent...
BC Week In Review | Feb 20, 2012
Clinical News

Menveo regulatory update

Novartis said it received a complete response letter from FDA for an sBLA for Menveo to prevent invasive disease caused by Neisseria meningitides serogroups A, C, Y and W135 in infants and toddlers ages 2...
BC Extra | Feb 14, 2012
Company News

Complete response for Novartis' Menveo in infants, toddlers

Novartis AG (NYSE:NVS; SIX:NOVN) said it received a complete response letter from FDA for an sBLA for Menveo to prevent invasive disease caused by Neisseria meningitides serogroups A, C, Y and W135 in infants and...
BC Week In Review | Jun 20, 2011
Clinical News

Menveo regulatory update

FDA accepted for filing an sBLA from Novartis for Menveo to prevent invasive disease caused by Neisseria meningitides serogroups A, C, Y and W135 in infants and toddlers ages 2 months to 2 years of...
Items per page:
1 - 10 of 33